
Glaukos (GKOS) Stock Forecast & Price Target
Glaukos (GKOS) Analyst Ratings
Bulls say
Glaukos is viewed positively because its preliminary FY27 revenue guide of about $1B materially exceeds prior consensus of $852.4M, signaling that Epioxa, iDose, and the legacy MIGS franchise are all contributing to a faster-than-expected growth profile. The company’s 3Q26 results reinforce that thesis, with total revenue of $211.0M, gross margin near 85%, and positive non-GAAP earnings, while iDose generated about $76M and corneal health about $59M, showing two sizable growth engines. The investment case also benefits from improving commercialization access, with Epioxa supported across more than 90% of commercial lives and 80% of Medicaid lives, 700+ detection centers, and iDose still in early penetration, leaving room for further operating leverage and profit expansion.
Bears say
Glaukos is facing a fundamental risk profile driven by slower-than-expected MIGS market growth, which could limit demand for its core glaucoma devices and compress the company’s ability to scale revenue across its surgical portfolio. Its outlook is further pressured by uncertainty around adoption of iDose and infinite, along with the possibility of slower product launches than assumed, especially Epioxa in Corneal Health, which would delay commercialization benefits and weaken growth expectations. In addition, an expanding number of competitors and potential changes in the reimbursement landscape could intensify pricing pressure, reduce market share, and make execution more difficult across its ophthalmic platform.
This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.
Glaukos (GKOS) Analyst Forecast & Price Prediction
Start investing in Glaukos (GKOS)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Glaukos (GKOS) Forecast
Glaukos (GKOS) Analyst Forecast & Price Prediction
Start investing in Glaukos (GKOS)
Order type
Buy in
Order amount
Est. shares
0 shares